German pharmaceutical giant Merck KGaA has announced a deal to buy US biotech equipment maker Millipore in a deal valued at $7.2bn.
Millipore, which supplies tests and equipment to the biotechnology industry, confirmed at the end of February that it was contemplating a possible sale.
The company hired Goldman Sachs to act as a financial adviser and Cravath, Swaine & Moore LLP as a legal adviser to help it consider its options.
On 28 February Merck announced it would pay $107 per share in cash for Millipore and expects the deal will be completed in the second half of 2010.
The purported share price would mark a 50% premium to Millipore’s $71.34 closing stock price on 19 February, the last trading day before takeover reports surfaced.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData